secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2026-08-21T21:00:13+00:00
Accession:  0001213900-26-092657
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma receives Nasdaq bid price deficiency notice for ESLA
--------------------------------------------------------------------------

- Nasdaq notified on Aug 17, 2026 that ESLA bid price stayed below $1.00 for 30 straight days (Jul 6–Aug 14).
- Company has until Feb 16, 2027 (180-day period) to regain compliance via 10 consecutive days at $1.00+.
- Reverse stock split, if used, must be completed by at least 10 business days before compliance deadline.
- If not cured, possible second 180-day extension or delisting appeal; no immediate impact on listing/trading.
- Management evaluating options to regain bid price compliance; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026092657/0001213900-26-092657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026092657/ea0303066-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-092657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer